Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4

Tobias Zöller1, Mareike Wittenbrink1, Meike Hoffmeister2,3 and Alexander Steinle1*

1 Institute for Molecular Medicine, Goethe University Frankfurt am Main, Frankfurt am Main, Germany, 1 Institute of Biochemistry II, Goethe University Frankfurt am Main, Frankfurt am Main, Germany, 2 Brandenburg Medical School (MHB) Theodor Fontane, Institute of Biochemistry, Neuruppin, Germany

Stress-induced cell surface expression of MHC class I-related glycoproteins of the MIC and ULBP families allows for immune recognition of dangerous “self cells” by human cytotoxic lymphocytes via the NKG2D receptor. With two MIC molecules (MICA and MICB) and six ULBP molecules (ULBP1–6), there are a total of eight human NKG2D ligands (NKG2DL). Since the discovery of the NKG2D–NKG2DL system, the cause for both redundancy and diversity of NKG2DL has been a major and ongoing matter of debate. NKG2DL diversity has been attributed, among others, to the selective pressure by viral immunoevasins, to diverse regulation of expression, to differential tissue expression as well as to variations in receptor interactions. Here, we critically review the current state of knowledge on the poorly studied human NKG2DL ULBP4. Summarizing available facts and previous studies, we picture ULBP4 as a peculiar ULBP family member distinct from other ULBP family members by various aspects. In addition, we provide novel experimental evidence suggesting that cellular processing gives rise to mature ULBP4 glycoproteins different to previous reports. Finally, we report on the proteolytic release of soluble ULBP4 and discuss these results in the light of known mechanisms for generation of soluble NKG2DL.

Keywords: NKG2D, ULBP4, NK cells, shedding, antibodies

INTRODUCTION

NKG2D is an activating, homodimeric C-type lectin-like immunoreceptor almost exclusively, but broadly, expressed on human cytotoxic lymphocytes endowing such killer cells with the capacity to detect and destroy dangerous “self cells” by means of the “induced-self” recognition mode (1–4). Upon NKG2D ligation, activating signals are intracellularly transduced via the NKG2D-associated adaptor protein DAP10 with subsequent activation of the phosphatidylinositol-3-kinase and the Grb2-Vav signaling pathways (5, 6). These signaling pathways stimulate cellular cytotoxicity, but also promote cytokine secretion by NK cells, CD8 αβ T cells, and γδ T cells (3, 7–9). NKG2D-mediated “induced-self” recognition is facilitated by various MHC class I-related cell surface glycoproteins, which usually are not or barely expressed on “healthy” cells but are strongly upregulated at the cell surface upon cellular stress, exposure to PAMPs, viral infection, or malignant transformation, thereby promoting cytolysis of “harmful” cells through engagement of NKG2D (1, 4, 10).

In humans, there are eight known ligands for NKG2D including the two MHC-encoded and MHC class I chain-related glycoproteins A and B (MICA and MICB) as well as the six non-MHC-encoded, UL16-binding proteins (ULBP1–6) (1, 4, 11, 12). MICA/B molecules are comprised of an MHC class I-like α1α2 superdomain followed by an Ig-like α3 domain, a transmembrane domain, and a cytoplasmic domain (1, 4, 12, 13). By contrast, ULBP ectodomains comprise only the MHC class I-like α1α2 superdomain, which serves as NKG2D binding platform, and which is directly attached to the
cellular membrane via a glycosylphosphatidylinositol (GPI) anchor (ULBP1, -2, -3, and -6) or followed by a transmembrane domain and a short (ULBP4) or long (ULBP5) cytoplasmic tail, respectively (11, 12, 14, 15). More recently, it has been shown that the common truncated MICA allelic variant MICA*08 can also be membrane attached via a GPI anchor (16).

ULBP4 is encoded at the centromeric end of the ULBP gene cluster on the long arm of human chromosome 6 by the RAET1E locus (11, 17). ULBP4 glycoproteins have first been described in 2003 by Cosman and colleagues (18) as well as by Coukos and colleagues (19). Both groups identified ULBP4 based on in silico screens of human genomic sequences searching for relatives of the ULBP family members ULBP1, ULBP2, and ULBP3, which had previously been discovered during a search for binding partners of the HCMV glycoprotein UL16 and been named accordingly (14). Of note, ULBP4, like ULBP3, is not bound by the HCMV glycoprotein UL16 (18, 20, 21) and therefore can be considered a misnomer. Both original studies (18, 19) described ULBP4 cDNA encoding for a polypeptide of 263 amino acids (including the signal peptide) and giving rise to a mature cell surface-bound protein of 235 amino acids (~27 kDa). This ULBP4 polypeptide is encoded by four exons with exon 1 encoding for the signal peptide, exon 2 for the α1 domain, exon 3 for the α2 domain, and exon 4 for the short serine-rich stalk, the transmembrane region, and a short cytoplasmic domain (Figure 1A). This originally reported ULBP4 variant has meanwhile been termed isoform 1 by the Uniprot database1 (22). Five additional ULBP4 isoforms (isoforms 2–6) are referenced in the Uniprot database originating from alternative splicing (23, 24) and will be discussed later. Sequence analyses and phylogenetic trees constructed from the comparison of ULBP α1α2 superdomains strongly suggest that ULBP4 has diverged from other primate ULBP molecules earliest and before the separation of Old and New World monkeys (25). In addition, ULBP4 is the most polymorphic member of the ULBP family of proteins (11, 26, 27), although there is no functional rationale for this polymorphism. There are some reports of ULBP4 being expressed by various tumors, EBV-infected B cells, and cytokine-activated NK cells that may be relevant for the NKG2D-mediated immunosurveillance and immunoregulation in these settings (28–33). In our approach to this peculiar NKG2D, we realized that ULBP4 glycoproteins are poorly characterized and that there exist substantial inconsistencies when comparing the literature and publicly available databases on rather basic issues such as on biochemical properties and expression by cell lines and tissues. Hence, we set out to study expression and biochemical properties of ULBP4 molecules.

MATERIALS AND METHODS

Cells
C1R and HepG2 cells were cultivated in RPMI 1640 (Sigma-Aldrich, St. Louis, MO, USA), HCT116 and HaCaT cells in Iscove’s Modified Dulbecco’s Medium (Sigma-Aldrich), and Hela cells in Dulbecco’s Modified Eagle Medium (Thermo Fisher Scientific, Waltham, MA, USA). All media were supplemented with 10% FCS (Biochimie, Berlin, Germany), 2 mM l-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (both from Sigma-Aldrich), and RPMI 1640 in addition with 1 mM sodium pyruvate (Thermo Fisher). 293F cells were cultivated in FreeStyle™ F17 Expression Medium (Thermo Fisher) with 0.1% Pluronic F-68 (Thermo Fisher), 100 U/ml penicillin, 100 mg/ml streptomycin, and 8 mM l-glutamine. C1R stably transfected with RSV 5neo containing the cDNA MICA*07, MICA*08 (21), ULBP4 (isoform 0), and ULBP4 (isoform 1) were cultivated in presence of 1.8 mg/ml G418.

Antibodies
Anti-ULBP4 mAb clone 709116 and ULBP4-specific goat polyclonal antibodies (pAb) were from R&D (Minneapolis, MN, USA), anti-ULBP4 mAb clone 666 from Santa Cruz (Dallas, TX, USA) and the anti-hexahistidine-tag mAb His.H8 from Thermo Fisher. Secondary staining reagents allopbycycocyanin-conjugated goat anti-mouse Ig (GAM-APC), Alexa-Fluor-488-conjugated donkey anti-goat Ig (DAG-488), and phycoerythrin-conjugated streptavidin (SA-PE) were from Jackson ImmunoResearch (West Grove, PA, USA). MICA-specific mAb AMO1 and MICA/B-specific mAb BAM03 were previously described (34). Anti-ULBP4 mAb DUMO1 was generated by immunizing BALB/c mice with P815-ULBP4 transfectants and soluble ULBP4 (sULBP4) by standard hybridoma technology as previously described (35) and isotyped as IgG1. Supernatants of hybridoma were screened for binding to 293-ULBP4 transfectants by flow cytometry. DUMO1 binds to P815, 293, and COS-7 cells transfected with ULBP4, but not to the respective mock transfected, and DUMO1 does not cross-react with ULBP1, ULBP2, and ULBP3, respectively (data not shown).

Flow Cytometry
Cells were harvested, washed twice with fluorescence-activated cell sorter (FACS) buffer (PBS, 2% FCS, 2 mM EDTA, and 0.01% sodium azide) and stained with 10 µg/ml of the primary antibody for 20 min at 4°C. Then, cells were washed again with FACS buffer and stained with DAG-488 (10 µg/ml) or GAM-APC (1.25 µg/ml) for 20 min at 4°C. After additional washing, flow cytometry analyses were performed using a FACS Canto II (BD Biosciences, Heidelberg, Germany) and data analyzed using FlowJo (Tree Star, Ashland, OH, USA). Biotinylated soluble truncated standard ULBP4 (sstULBP4) was immobilized on streptavidin-coated microspheres (Bangs Laboratories, Fishers, IN, USA) by incubating 5 µg microspheres with 5 µg/ml biotinylated sstULBP4 for 15 min at 4°C. Subsequently, sstULBP4-loaded microspheres were washed twice with FACS buffer, stained with antibodies, and analyzed by flow cytometry as described earlier. The specific fluorescence intensity was calculated by subtracting the median fluorescence intensity (MFI) of the isotype control from the MFI of the antibody of interest.

Production of sULBP4
A cDNA encoding for the first 222 amino acids of ULBP4 (Met 1 to Ser 222) was cloned into the pFUSE vector (InvivoGen, San Diego, CA, USA) in front of an AviTag and a hexahistidine tag

1http://www.uniprot.org/uniprot/Q8TD07 (Accessed: January 31, 2018).
Figure 1

| ULBP4 isoforms generated by differential splicing. (A) Differential usage of an internal splice site in exon 4 gives rise to the major full-length ULBP4 isoforms 0 and 1, respectively, while exclusion of exon 4 by alternative splicing (stippled lines) gives rise to the putatively secreted soluble ULBP4 isoform 3. Depicted is the exon–intron structure of the ULBP4/RAET1E gene and the alternatively spliced gene products representing isoforms 0, 3, and 1. (B) Amino acid sequence alignment of ULBP4 isoform 1 (upper; GenBank accession no. AY252119 (18)) and isoform 0 (lower; GenBank accession no. MH020173). Exon boundaries are indicated by black triangles except for the exon 4/5 boundary of isoform 0 (open triangle). N-linked glycosylation sites are underlined with asparagines in bold. Signal peptide sequence (Met 1 to Gly 30) is italicized, transmembrane domain highlighted in gray. Disulfide bond between Cys 126 and Cys 189 highly conserved in the MHC class I fold is indicated. (C) Scheme of ULBP4 isoforms 0, 1, and 3 with N-glycosylation sites indicated by pins. |
(Figure 2A) replacing the IL-2 signal sequence and the Fc-encoding region of the vector. The resulting plasmid encoding for soluble carboxyterminally truncated and tagged ULBP4 (stULBP4) was used for transient transfection of 293F cells. Supernatants were harvested 4 days later and stULBP4 affinity-purified using HisPur™ Ni-NTA spin columns (Thermo Scientific) according to the manufacturer’s protocol. Eluted stULBP4 was concentrated using Amicon® Ultra Centrifugal Filter units (Merck, Darmstadt, Germany) and further purified by size exclusion chromatography using a Hiload™ 16/60 Superdex™ 200 column (GE Healthcare, Chicago, IL, USA) on an ÄKTA purifier (GE Healthcare). stULBP4 was collected and analyzed by SDS-PAGE (Figure 2B). For determining concentrations of sULBP4 and sMICA in culture supernatants, stULBP4 (His 31 to Ser 222 followed by an AviTag and a hexahistidine tag) or soluble truncated standard MICA07 (ststMICA) (Glu 24 to Gln 304 followed by an AviTag and a hexahistidine tag) was produced as described above for stULBP4 in 293F cells and purified by Ni-NTA spin columns except that the vector-encoded IL-2 signal sequence was placed in front of the coding regions of mature ULBP4 and MICA glycoproteins. Biotinylation of ststULBP4 was done using BirA Biotin-protein ligase (Avidity, Aurora, CO, USA) according to the manufacturer’s protocol.

### Quantitative Real-Time PCR

Cellular RNA was isolated using pegGOLD TriFast™ (Pqlab, Erlangen, Germany) according to the manufacturer’s protocol. RNA from human esophagus and skin was purchased from Thermo Fisher. RNA was treated with RNase-free DNase (Promega, Madison, WI, USA) and subsequently converted into cDNA using M-MLV RT RNAse (H− Point Mutant (Promega) according to the manufacturer’s protocol. Quantitative PCR (qPCR) was performed using SYBR Green technology (Roche, Basel, Switzerland) on a StepOnePlus Real-Time PCR System (Applied Biosystems, FosterCity, CA, USA). For amplification of ULBP4, oligonucleotides Ex3fw (5′-CTGGCTCAGGGAATTCTTAGG-3′) and Ex4rv (5′-CTAGAAGAAGACCTTGGATAC-3′) were used. To selectively amplify ULBP4 isoforms 0 or 1, the forward primer ULBP4-fw (5′-TACAGATAGGGAGCATCTCAGT-3′) was combined with the reverse primers ULBP4_iso0_rv (5′-CTAGGTGGATCTTGGCATT-3′) or ULBP4_iso1_rv (5′-CTAGACGTAAGCTCAGG-3′), respectively (all from Sigma-Aldrich). Copy numbers were normalized with the ΔΔCt method using 18S rRNA as previously described (35).

### Immunoblotting

HeLa cells were harvested, washed twice with PBS and resuspended with ice-cold NP40-Lysis-Puffer [1% NP40, 50 mM Tris, 150 mM NaCl, Complete Protease Inhibitor (Roche, Mannheim, Germany)]. Lysates were incubated for 20 min on ice and then centrifuged for 15 min at 17,000 g. ULBP4 was immunoprecipitated with biotinylated DUMO1 coupled to streptavidin magnetic beads (Thermo Fisher Scientific) for 3 h at 4°C. Immunoprecipitates were washed several times and eluted using denaturation buffer [0.5% SDS, 40 mM dithiothreitol (DTT)] for 5 min at 95°C. Deglycosylation was performed using endoglycosidase H or peptide-N-glycosidase F (both from New England Biolabs, Ipswich, MA, USA) according to the manufacturer’s protocols. Immunoprecipitates were separated using SDS-PAGE and blotted onto a PVDF membrane (Carl Roth, Karlsruhe, Germany). Membrane was blocked using 5% non-fat dried milk powder (AppliChem) in TBST (150 mM NaCl, 10 mM Tris, 0.1% Tween 20) and then probed with 2 µg/ml ULBP4-specific pAb, and subsequently with 0.16 µg/ml HRP-conjugated donkey anti-goat-Ig (Santa Cruz). Immunoblots were developed with HRP-Juice Plus (PJK, Kleinbittersdorf, Germany) using a Fusion SL imaging system (Vilber Lourmat).

![Figure 2](https://example.com/figure2.png) **Figure 2** Aminoterminal of mature ULBP4 glycoproteins. (A) Scheme of soluble carboxyterminally truncated and tagged ULBP4 (stULBP4) used for mass spectrometric analyses. (B) Affinity-purified stULBP4 from supernatants of transfected 293F cells was treated either with PNGaseF (P) or left untreated (ø), separated by SDS-PAGE, and visualized by Coomassie staining. (C) Abundancy of aminoterminal stULBP4 fragments as determined by mass spectrometry. stULBP4 was digested with trypsin and LysC, and resulting fragments were analyzed and counted by mass spectrometry.
Detection of sULBP4 and sMICA

For detection of sULBP4 and sMICA, anti-ULBP4 pAb (R&D Systems) or mAb AMO1 were immobilized on MagPlex-C microspheres (Luminex, Austin, TX, USA), respectively, according to the manufacturer's instructions. Cell culture supernatants were diluted 1:1 in PBS with 1% BSA (dilution buffer) and added together with SA-PE and either biotinylated DUMO1 (for sULBP4 detection) or biotinylated BAMO3 (for sMICA detection) to 500 microspheres. Standard curves were generated by titrating ststULBP4 or ststMICA. Samples were incubated overnight at room temperature, washed twice in dilution buffer, and measured on a Luminex 100 system (Luminex). All samples were measured in triplicates.

In-Solution Digestion

Purified stULBP4 protein samples were precipitated with acetone, and subsequently in-solution digestion was performed as described (36). In brief, protein pellets were washed and resuspended in denaturation buffer containing 6 M urea and 2 M thiourea. Proteins were reduced with 1 mM DTT, alkylated with 5.5 mM iodoacetamide and digested with the endopeptidase LysC (Wako) for 3 h and sequencing-grade trypsin (Promega) overnight. Peptide mixtures were concentrated and desalted using the Stop and Go Extraction technique (37).

Liquid Chromatography and Mass Spectrometry

A binary buffer system consisting of buffer A (0.1% formic acid) and buffer B (80% acetonitrile, 0.1% formic acid) was used for peptide separation on an Easy-nLC 1200 (Thermo Fisher Scientific). This system was coupled via a nano electrospray ionization source to the quadrupole-based Q Exactive HF benchtop mass spectrometer (38). Peptide elution from the in-house packed 18 cm (1.9 µm C18 Beads, Dr. Maisch Germany) column was achieved by increasing the relative amount of B from 10 to 38% in a linear gradient within 23 min at a column temperature of 40°C. Followed by an increase to 100%B within 7 min and gradients were completed by a re-equilibration to 5% B. Q Exactive HF settings: MS spectra were acquired using 3E6 as an AGC target, a maximal injection time of 20 ms and a 60,000 resolution at 300 m/z. The mass spectrometer operated in a data-dependent Top15 mode with subsequent acquisition of higher-energy collisional dissociation fragmentation MS/MS spectra of the top 15 most intense peaks. Resolution for MS/MS spectra was set to 15,000 at 200 m/z, AGC target to 1E5, maximal injection time to 25 ms and the isolation window to 1.6 Th.

Mass Spectrometry Data Processing and Analysis

All acquired raw files were processed using MaxQuant (1.5.3.30) (39) and the implemented Andromeda search engine (40). For protein assignment, electrospray ionization-tandem mass spectrometry (ESI-MS/MS) fragmentation spectra were correlated with the Uniprot human database (v. 2017) with manually added peptide sequences of ULBP4 starting with all possible N-termini of the mature protein. Searches were performed with tryptic specifications and default settings for mass tolerances for MS and MS/MS spectra. Carbamidomethyl at cysteine residues was set as a fixed modification, while oxidation at methionine, acetylation at the N-terminus, and conversion from Asn to Asp were defined as variable modifications. The minimal peptide length was set to seven amino acids, and the false discovery rate for proteins and peptide spectrum matches to 1%. The match-between-run feature was used with a time window of 0.7 min.

Statistics

Statistical analyses as detailed in the figure legends were performed using Prism 7 (GraphPad, San Diego, CA, USA).

RESULTS

Aminoterminus of Mature ULBP4 Glycoproteins Is Recessed

We noted conflicting predictions for the aminoterminus of mature ULBP4 glycoproteins. In the original reports, the aminoterminus of mature ULBP4 glycoproteins, as generated by cleavage of the putative aminoterminus signal peptide, has been assigned in the absence of experimental evidence to glycine 29 along the exon 1/exon 2 boundaries (18, 19) presumably based on sequence alignments with other ULBP and MHC class I-related molecules (Figures 1A,B). However, we noted that the database Uniprot (22), in contrast to the existing literature, had assigned the aminoterminus of mature ULBP4 molecules to histidine 31 based on “manual assertion according to rules” (see text footnote 1). To clarify these conflicting predictions, we addressed this issue experimentally: soluble, carboxyterminally truncated and tagged ULBP4 ectodomains encompassing the α1, the α2 domain, and most of the serine-rich region, preceded by the “natural” ULBP4 signal peptide (stULBP4; Met 1 through Ser 222) were ectopically expressed in 293F cells, purified from the supernatants by Nickel-NTA spin columns (Figures 2A,B), fragmented by digestion with trypsin and LysC, and resulting stULBP4 fragments were subjected to liquid chromatography–mass spectrometry (LC–MS). Mass spectrometry identified all expected tryptic fragments almost completely covering the mature stULBP4 polypeptide (data not shown). The aminoterminus of mature ULBP4 molecules, however, is generated by cleavage of the signal peptide during cotranslational translocation into the ER, and, accordingly, potentially resulting in the peptides GGHSLCFNFTIK, GHSLCFNFTIK, or HSLCFNFTIK, respectively, depending on the actual cleavage site. While the fragment HSLCFNFTIK was detected at high abundance, the peptides GGHSLCFNFTIK and GHSLCFNFTIK were not or only very rarely detected (Figure 2C). These data strongly suggest that mature ULBP4 glycoproteins start with histidine 31 in line with the prediction by Uniprot and not as previously assumed with glycine 29. It remains to be determined how such a recessed β1 strand of the ULBP4 α1 domain may impact ULBP4 folding and function differently as compared with other ULBP molecules. Our mass spectrometric analyses also showed that the three putative N-glycosylation sites predicted by Uniprot at Asn 36 (α1 domain), Asn 154 (α2 domain),
and Asn 212 (serine-rich region) all were glycosylated. In addition, we also detected N-linked glycosylation at Asn 82 (Figures 1B,C). Position 82 is polymorphic and occupied either by asparagine (stULBP4) or tyrosine (Uniprot reference sequence at http://www.uniprot.org/uniprot/Q8TD07), and therefore ULBP4 glycosylation can be expected to be variable within the human population with potential consequences for expression and detection. While Asn 82, Asn 154, and Asn 212 were glycosylated in almost all (>99%) tryptic fragments analyzed, glycosylation efficiency at Asn 36 appeared slightly reduced with ~90% of the fragments glycosylated (data not shown).

**Carboxyterminus of ULBP4 Is Variable due to Alternative Splicing**

Original studies of ULBP4 reported that exon 4, in addition to the serine-rich stalk region, entirely encodes for both transmembrane and cytoplasmic ULBP4 residues (18, 19) (Figure 1). In the course of our studies on ULBP4, we characterized a commercially available EST clone (clone 601076687F1) derived from a cervical carcinoma cell line encoding for a ULBP4 variant with a divergent carboxyterminus (GenBank accession no. MH020173). This ULBP4 variant differs from the originally published sequence by an alternate and shorter cytoplasmic tail which is created by alternative splicing due to an alternative splice donor site within exon 4 (Figure 1). Accordingly, the 5’ portion of exon 4 is merged in frame with an additional exon located ~4 kb downstream (exon 5) which encodes the four carboxyterminal amino acids followed by a long 3’ UTR (Figure 1). Consequently, such ULBP4 isoforms have a distinct cytoplasmic domain shortened by eight amino acids as compared with the originally reported ULBP4 isoform 1 (Figure 1) (18, 19). In addition, Uniprot lists five other ULBP4 isoforms (isoforms 2–6) based on reports of alternatively spliced transcripts for which experimental evidence of protein expression is lacking or scarce (see text footnote 1). Among these, isoform 3 is the only isoform that also includes exon 5 as reported here for the new ULBP4 isoform. Isoform 3 was identified in the course of a broad screen by the secreted protein discovery initiative (24) that used computational and experimental approaches to identify human cDNA clones encoding for putatively secreted proteins preceded by a signal peptide. Of note, the cDNA of isoform 3 is composed of exons 1, 2, 3, and 5, but lacks exon 4 which encodes for the transmembrane region. Hence, isoform 3 corresponds to an alternatively spliced and potentially soluble isoform of the new full-length ULBP4 isoform reported here to which we refer as isoform 0 in the following (Figure 1). The original studies have shown that ULBP4 isoform 1 can be expressed at the cell surface of transfected cell lines and is functionally recognized by NK cells (18, 19). To assess whether the newly reported isoform 0 likewise gives rise to a ULBP4 glycoprotein that can be functionally expressed at the cell surface and consequently be recognized via NKG2D by NK cells and T cells, we generated a ULBP4-specific mAb.

**ULBP4 Antibodies**

The ULBP4-specific mAb DUMO1 was generated by immunizing mice with mouse mastocytoma cells P815 stably transfected with ULBP4. DUMO1 binds to ststULBP4 immobilized on microspheres (ststULBP4_im), but not to control microspheres (Figure 3A). DUMO1 also bound to 293F cells and CIK cells transfected with either ULBP4 isoform 0 or isoform 1, but not to the corresponding mock transfectants (Figures 3C,D). Apart from corroborating specificity of DUMO1 for cellular ULBP4, these data also demonstrate that ULBP4 isoform 0 can be broadly expressed at the cell surface. While our data also indicate that ULBP4 isoform 0 may allow for a brighter surface expression than ULBP4 isoform 1, this possibility needs to be validated by further experiments. For control, we included the few commercially available antibodies said to be ULBP4-specific. While ULBP4-specific pAb and mAb 709116 bound ststULBP4_im and ULBP4 transfectants similarly to DUMO1, we did not detect binding of mAb 6E6 neither to ststULBP_im nor to the ULBP4 transfectants by flow cytometry (Figures 3A,B), although mAb 6E6 brightly detected denatured ststULBP4 in immunoblotting (data not shown). mAb 6E6 has previously been used to demonstrate ULBP4 surface expression on EBV-infected cells and on placental exosomes (31, 41) as well as on ULBP4 transfectants which is puzzling in the light of our results.

**ULBP4 Expression**

Among human tissues, we found ULBP4 transcripts by qPCR most abundantly in tissues which are of ectodermal origin such as skin, esophagus, and cervix (data not shown). A preferential ULBP4 expression in human skin has already been reported by Cosman and colleagues (18) and a strong expression bias toward tissues of ectodermal origin is also documented by publicly available databases. We wondered whether isoforms 0 and 1 may be differentially expressed in such tissues but detected both at a comparable abundance in both skin and esophagus (Figure 4A). Assessing abundance of ULBP4 transcripts in a broad variety of human tumor cell lines, we detected ULBP4 transcripts most abundantly in the cervix carcinoma cell line HeLa, whereas ULBP4 transcripts were undetectable in liver cancer cells HepG2 or in the erythroleukemia line K562 (Figure 4B and data not shown) well in line with publicly available data sets. Of note, pronounced ULBP4 surface expression has been claimed based on binding of mAb 709116 to HepG2 cells by the supplier, for the erythroleukemia line K562 (42) and for cytokine-activated NK cells (32). By using DUMO1 and ULBP4-specific pAb, we were unable to detect ULBP4 surface expression on HeLa, HepG2, HCT116, and HaCat cells, respectively. By contrast, mAb 709116 bound to a substantial portion of HCT116 cells and brightly stained HepG2 cells (Figure 4D) as reported by the supplier and as previously reported for another not publicly available mAb (29), although we were unable to detect ULBP4 transcripts in HepG2 cells. Collectively, our data on mAb 6E6 and 709116 advise substantial caution when interpreting results obtained with these commercially available ULBP4 antibodies.

---

1. https://www.scbt.com/scbt/product/ulbp4-antibody-6e6 (Accessed: January 31, 2018).
2. https://www.proteinatlas.org/ENSG00000164520-RAET1E/cell (Accessed: January 31, 2018).
3. https://www.proteinatlas.org/ENSG00000164520-RAET1E/tissue (Accessed: January 31, 2018).
4. https://www.proteinatlas.org/ENSG00000164520-RAET1E/col (Accessed: January 31, 2018).
5. https://www.proteinatlas.org/ENSG00000164520-RAET1E/mouse (Accessed: January 31, 2018).
and strongly suggest to validate such data by independent methodological approaches such as by qPCR and/or immunoblotting. Our data also indicate that in contrast to other NKG2DL such as MICA, MICB, and ULBP1–3, which are frequently expressed on a broad variety of human tumor cell lines (43), ULBP4 may be not or only sparsely expressed on the surface of human tumor cell lines. In fact, immunoblotting of lysates of HeLa cells revealed that the vast majority of detectable ULBP4 glycoproteins is sensitive for digestion with endoglycosidase H, and therefore retained intracellularly in the ER or Golgi complex well in accordance with the lack of detectable cell surface expression (Figures 4C,D). Assessing expression of ULBP4 isoform 1 versus isoform 0 in more than 30 human cell lines, we found that three cell lines including HeLa cells (HeLa, LNCaP, and MG-63) and primary keratinocytes expressed both isoforms, 8 cell lines expressed only isoform 0, but none expressed only isoform 1 (data not shown). Based on these findings, one may consider the possibility that the previously reported isoform 1 rather is a byproduct of inefficient splicing of ULBP4 primary transcripts, whereas isoform 0 may represent the physiologically more relevant isoform. Future research on ULBP4 should take such considerations into account.

**Soluble ULBP4**

Isoform 3 may represent a soluble variant of ULBP4 generated by alternative splicing of the full-length isoform 0 excluding exon 4 (Figure 1). However, evidence for isoform 3 thus far relies only on analyses of transcripts/cDNA, but not on protein data (24). Therefore, existence and secretion of sULBP4 based on isoform 3 transcripts has to await validation by experimental evidence. In addition, there are reports claiming the existence of other sULBP4 isoforms generated by alternative splicing (23, 44). However, for the originally reported soluble RAET1E2 isoform (Uniprot isoform 4) (44), no corresponding transcripts could be detected in a subsequent study by the same group (23). This latter study reported three other rarely occurring ULBP4 splice variants all comprising the entire exon 4 encoding for the transmembrane domain. Accordingly, these variants (Uniprot isoforms 2, 5, and 6) reportedly are cell membrane-bound variants (23), which obviously cannot be secreted without further processing. Considering physiologic expression of ULBP4 in skin, we assessed freshly isolated human keratinocytes for ULBP4 transcripts. By pairing a primer located in exon 1 with a reverse primer in the 3' end of exon 4 (isoform 1) or in the 5' end of exon 5 (isoform 0), respectively, we detected predominant expression...
of transcripts corresponding to both full-length isoforms 0 and 1. At considerably lower frequency, we also detected transcripts corresponding to isoforms 2 and 3, but not to isoforms 4–6 (data not shown). Hence, our data indicate, that sULBP4 may be generated physiologically by alternative splicing under exclusion of exon 4 (i.e., ULBP4 isoform 3) although existence of such sULBP4 glycoproteins remains to be shown experimentally. We and others had previously reported that most human NKG2DL can be released from cells either by proteolytic shedding or by exosomal secretion (12, 34, 45–47). MICA (but not MICA*08), MICB, and ULBP2 have been shown to be shed by metalloproteases such as ADAM10, ADAM17, and MMP14 (48–51) while MICA*08 and ULBP3 were shown to be preferentially released in exosomes (45, 52). However, neither proteolytic shedding nor exosomal release has been reported for ULBP4 possibly due to the scarcity of bona fide ULBP4-specific antibodies.

To address release of sULBP4 from ULBP4-expressing cells, we established a sandwich assay specifically detecting sULBP4 using immobilized anti-ULBP4 pAb and biotinylated mAb DUMO1. Using this assay, sULBP4 was clearly detectable in supernatants of C1R cells stably transfected with ULBP4 isoforms 0 and 1, respectively (Figure 5B). To assess whether metalloproteases are involved in the generation of sULBP4, we added batimastat (BB-94), a potent, broad spectrum metalloprotease inhibitor, to cultures of C1R transfectants. As expected and in line with the previous reports, addition of BB-94 to C1R-MICA*07 and C1R-MICA*08 cells inhibited release of sMICA*07, but not of sMICA*08, in a dose-dependent manner (Figure 5A). Of note, release of sULBP4 from both C1R-ULBP4 transfectants was also inhibited in a BB-94 dose-dependent manner demonstrating that both ULBP4 isoforms 0 and 1 can give rise to sULBP4 due to the action of metalloproteases (Figures 5B,C). Finally,
we assessed sULBP4 in the culture supernatants of various cell lines expressing ULBP4 transcripts (Figure 4B). In line with the highest abundance of ULBP4 transcripts in HeLa cells, we only detected low amounts sULBP4 in the supernatants of HeLa cells (Figure 5D), but not of HCT116, HepG2, and HaCat cells (data not shown). Release of sULBP4 by HeLa cells could only partially be blocked by addition of BB-94 (Figure 5D) indicating that HeLa cells generate sULBP4 not only by shedding of full-length isoforms 0 and/or 1 through metalloproteases. Since we detected in HeLa cells both transcripts of ULBP4 isoform 3 (data not shown) and ULBP4 proteins of a molecular mass corresponding to isoform 3 (Figure 4C), secretion of isoform 3 may explain the BB-94 independent release of sULBP4 by HeLa cells.

CONCLUDING REMARKS

ULBP4 glycoproteins are among the least characterized human NKG2D ligands. Our present study suggests that this may be explained by a highly restricted expression in tissues and by cell lines as well as by the scarcity and deficiency of commercially available antibodies. While prevalence of ULBP4 transcripts indicates a strong expression bias toward tissues and cell lines of ectodermal origin, physiologic and cellular expression of ULBP4 glycoproteins by such cells remains to be addressed by future research. We here provide evidence that the aminoterminus of mature ULBP4 molecules is recessed when compared with other ULBP molecules and that also the carboxyterminus of at least a substantial portion of sULBP4 secreted by HeLa cells is due to the alternatively spliced isoform 3. Of note, most ULBP4 glycoproteins were intracellularly retained in HeLa cells as evident from their lack of EndoH resistance and lack of surface expression, and it remains to be determined by future studies whether this is...
a peculiar feature of HeLa cells or a general property of ULBP4. In addition, it will be of considerable interest to determine occurrence of sULBP4, either proteolytically shed or as secreted isoform 3, in healthy or diseased state such as in patients with skin or cervical tumors. Altogether, we propose that ULBP4 should not regarded as just another NKG2DL, but that the unique cellular expression and processing of ULBP4 together with the early evolutionary separation from other ULBP family members indicates a peculiar function within the framework of NKG2D-mediated immunosurveillance.

ETHICS STATEMENT

Study includes analyses of buffy coats obtained from the Blood Donor Service Baden-Wuerttemberg-Hessen, Frankfurt am Main, after approval by the Ethics committee of the Goethe University of Frankfurt. Study includes generation of monoclonal antibodies based on immunization of mice which was carried out in accordance with current laws for animal research and approved by the Regierungspräsidium Tübingen and Darmstadt.

REFERENCES

1. Ullrich E, Koch J, Cerwenka A, Steine A. New prospects on the NKG2D/ NKG2DL system for oncology. Oncogene (2013) 2:62097. doi:10.4161/onc.20697
2. Waldhauer I, Steine A. NK cells and cancer immunosurveillance. Oncogene (2008) 27:5932–43. doi:10.1038/onc.2008.267
3. Bauer S, Groh V, Wu J, Steine A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 285:727–9. doi:10.1126/science.285.5428.727
4. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 31:413–41. doi:10.1146/annurev-immunol-032712-090951
5. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphorylnoositol-3-kinase in human natural killer cells. Nat Immunol (2006) 7:524–32. doi:10.1038/ni.1325
6. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science (1999) 285:730–2. doi:10.1126/science.285.5428.730
7. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity (2002) 17:19–29. doi:10.1016/S1074-7613(02)00333-3
8. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8+ T cells by NKG2D via engagement by MHC induced on virus-infected cells. Nat Immunol (2001) 2:255–60. doi:10.1038/85321
9. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steine A, Herrmann T. Activation of V gamma 9 delta T 2 cells by NKG2D. J Immunol (2005) 175:2144–51. doi:10.4049/jimmunol.175.4.2144
10. Lanier LL. NKG2D receptor and its ligands in host defense. Front Immunol (2015) 3:575–82. doi:10.1186/s13236-0066.CIR-15-0098
11. Carapito R, Bahram S. Genetics, genomics, and evolutionary biology of NKG2D ligands. Immunolet (2015) 267:88–116. doi:10.1111/imr.12328
12. Fernandez-Messina L, Reyburn HT, Vales-Gomez M. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol (2012) 3:299. doi:10.3389/fimmu.2012.00299
13. Li P, Morris DL, Willcox BE, Steine A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol (2001) 2:443–51. doi:10.1038/87757
14. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 14:123–33. doi:10.1016/S1074-7613(01)00095-4
15. Steine A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologues of the mouse RAE-1 protein family. Immunogenetics (2001) 53:279–87. doi:10.1007/s002510100325
16. Ashiro O, Lopez-Cobo S, Fernandez-Messina L, Pontes-Quero S, Pandolfi R, Reyburn HT, et al. A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008. Biochem J (2013) 454: 295–302. doi:10.1042/Bj20130194
17. Radosavljevic M, Cuillierier B, Wilson MJ, Clement O, Wicker S, Gilfillan S, et al. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2–q25.3. Genomics (2002) 79:114–23. doi:10.1006/geno.2001.6673
18. Chalupny NJ, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun (2003) 305:129–35. doi:10.1016/S0006-291X(03)00714-9
19. Conejo-Garcia JR, Benencia F, Courreges MC, Khang E, Zhang L, Mohamed-Hadley A, et al. Letal, a tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther (2003) 2:446–51. doi:10.4161/cbt.2.4.479
20. Muller S, Zocher G, Steine A, Stehle T. Structure of the HCMV UL16- MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands. PLoS Pathog (2010) 6:e1000723. doi:10.1371/journal.ppat.1000723
21. Spreu I, Stehle T, Steine A. Human cytomegalovirus-encoded UL16 discriminates MHC molecules by their alpha2 domains. J Immunol (2006) 177:5143–9. doi:10.4049/jimmunol.177.5.5143
22. The UniProt C. UniProt: the universal protein knowledgebase. Nucleic Acids Res (2017) 45:D158–69. doi:10.1093/nar/gkw1099
23. Cao W, Xi X, Wang Z, Dong L, Hao Z, Cui L, et al. Four novel ULBP splice variants are ligands for human NKG2D. Int Immunol (2008) 20:981–91. doi:10.1093/intimm/dnx057
24. Clark HE, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 13:2265–70. doi:10.1101/gr.1293003
25. Kasahara M, Sutoh Y. Comparative genomics of the NKG2D ligand gene family. Immunol Rev (2015) 267:72–87. doi:10.1111/imr.12320
26. Cox ST, Laza-Briviesca R, Madrigal JA, Sauvemont A. Further polymorphism of the RAET1/ULBP4 gene in humans. Tissue Antigens (2014) 84:435–7. doi:10.1111/tan.12383
27. Antoun A, Jobson S, Cook M, O’Callaghan CA, Moss P, Briggs DC. Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: extensive polymorphisms and evidence of diversity between human populations. Hum Immunol (2010) 71:610–20. doi:10.1016/j. humimm.2010.02.018

AUTHOR CONTRIBUTIONS

TZ, MH, and MW designed and performed experiments and analyzed data. AS conceptualized study, designed experiments, and wrote the manuscript with the support of TZ and MH.

ACKNOWLEDGMENTS

The authors thank Christina Born for excellent technical assistance.

FUNDING

This work was funded by institutional funds of the Institute for Molecular Medicine.
